Innoviva Market Cap 2010-2025 | INVA

Innoviva market cap history and chart from 2010 to 2025. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Innoviva market cap as of June 20, 2025 is $1.32B.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.318B $0.359B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $722.866B 55.43
Johnson & Johnson (JNJ) United States $360.406B 14.90
AbbVie (ABBV) United States $327.315B 18.04
Roche Holding AG (RHHBY) Switzerland $250.015B 0.00
Novartis AG (NVS) Switzerland $244.555B 13.97
Merck (MRK) United States $198.522B 10.15
Pfizer (PFE) United States $136.278B 7.47
Sanofi (SNY) France $117.375B 11.56
Bayer (BAYRY) Germany $30.180B 6.14
Novo Nordisk (NVO) Denmark $0.000B 21.83